A panelist discusses how the findings in the docetaxel-naive population show distinct differences in treatment efficacy, with potentially greater benefits observed for certain androgen receptor ...

A panelist discusses how these comparative results could influence clinical decision-making by suggesting potentially different magnitudes of benefit between enzalutamide and darolutamide depending on ...

“It is likely that more and more, these newer agents are going to play earlier and more central roles in the early treatment of BCG-unresponsive disease," says Shreyas S. Joshi, MD, MPH. He explained, ...

The Glean Urodynamics System received FDA clearance, offering wireless, catheter-free monitoring for lower urinary tract dysfunction, improving patient comfort and data accuracy. The SureForm 45 ...

A discussion on evolution of surgical education, importance of video training, and the future of patient-centered care in reconstruction. Welcome back to Pearls & Perspectives! In this episode of ...

TAR-200 monotherapy achieved a 6-month DFS of 85.3% and a 9-month DFS of 81.1% in BCG-unresponsive high-risk NMIBC patients. The trial reported high PFS (95.6%) and OS (98.0%) rates at 9 months, with ...

Kevin C. Zorn, MD, FRCSC, FACS, recaps the AUA 2025 session, “State-of-the-Art Lecture: Preservation of Ejaculatory Function with BPH Treatments." Preservation of ejaculatory function is a top ...

Welcome back to Pearls & Perspectives! In this episode of Pearls & Perspectives from Urology Times, Amy Pearlman, MD, interviews Rachel Rubin, MD, a urologist and fellowship-trained sexual medicine ...

Darolutamide plus ADT in mHSPC patients led to significantly lower PSA responses compared to ADT alone, enhancing clinical outcomes. Ultra-low PSA responses (<0.02 ng/mL) correlated with prolonged ...

Welcome back to Pearls & Perspectives, with Amy Pearlman, MD! In this episode of Pearls & Perspectives from Urology Times, host Amy Pearlman, MD, sits down with the legendary Larry Lipshultz, MD, ...

Cxbladder Triage test reduces cystoscopy and imaging in low-risk microscopic hematuria patients, optimizing diagnostic workflows. The study involved 3,353 patients, showing decreased cystoscopy and CT ...

Neal D. Shore, MD, FACS, shares the background and key findings from the phase 3 CREST trial, exploring sasanlimab plus BCG for BCG-naive NMIBC. Data from the phase 3 CREST trial (NCT04165317) ...